Qiming Venture Partners USA announced the promotions of two key members of its investment team.
Anna French, DPhil, based in the Boston area office, and Colin Walsh, PhD, based in the San Francisco Bay area office were promoted to partner from their prior positions as principals.
Dr. French joined Qiming US in 2017. She currently serves on the boards of WindMIL Therapeutics, Jasper Therapeutics and Umoja Biopharma, as well as a number of seed stage companies. Dr. French is also a board observer for several Qiming US portfolio companies. She was instrumental in the 2019 raise of the Qiming US Healthcare Fund II. Prior to joining Qiming US, Dr. French was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on strategy and operations. Before joining BCG, Dr. French led a global industry-academic consortium focused on cell therapy commercialization.
Dr. Walsh joined Qiming US in April 2019. He currently serves on the boards of Elevation Oncology and Korro Bio and is a board observer of Amphivena Therapeutics and Icosavax. Before joining Qiming US, Dr. Walsh was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to ND, Dr. Walsh held several roles as an early employee at Precision NanoSystems, a 5AM Ventures backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations.
Qiming Venture Partners was founded in China in 2006 and has over $5.5 billion in total assets under management. In January 2017, Qiming launched its first US-based fund, focused on early-stage healthcare opportunities in the United States and Europe. Situated in the major life science hubs of Cambridge, the San Francisco Bay Area and Seattle, it is led by Gary Rieschel and Mark McDade.